acePrognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma
While survival outcomes in multiple myeloma (MM) have improved with contemporary combination therapies, predicting disease trajectories for individual patients at diagnosis remains a significant challenge. We investigate the prognostic value of a noninvasive biomarker-cell-free DNA (cfDNA)‑derived 5-hydroxymethylcytosine (5hmC) signature-in newly diagnosed MM, aiming to improve risk stratification at diagnosis. In this prospective cohort study, 321 patients with newly diagnosed MM were enrolled between 2010 and…
A machine-learning derived weighted score from 18 cfDNA 5hmC-modified genes at diagnosis predicted overall and progression-free survival in newly diagnosed multiple myeloma after adjusting for stage and other clinical factors.
Findings are from a single prospective cohort enrolled 2010-2017 and authors state further independent validation is needed before clinical use within contemporary risk stratification.
Evidence
- Peer-reviewedJCO Precision Oncology2026-07-23
How should this claim be treated?
Truvace Impact Record TRV-2026-0554, v1: “Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma.” Truvace, 2026-07-24. /record/TRV-2026-0554 (accessed at citation time). sha256 2c2f4e8f352dce65…
Calibration history
Every change to this record since certification, in the open. None yet — the reading has held since it entered the record.
Certified into the record
How to verify without trusting this page
Fetch the canonical text of any version from /api/record/TRV-2026-0554 and hash it yourself — for example shasum -a 256 on the saved canonical field. The result must equal content_hash, and each version’s text ends with prev:followed by the prior version’s hash (version 1 chains to 64 zeros). If a single character of any version had been altered since certification, the chain would not reproduce.